Masimo (NASDAQ:MASI) Releases Q3 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its third quarter earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.81-0.86 for the period, compared to the consensus earnings per share estimate of $0.84. The company issued revenue guidance of $495-515 million, compared to the consensus revenue estimate of $502.87 million. Masimo also updated its FY 2024 guidance to 3.800-4.000 EPS.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. BTIG Research increased their target price on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Piper Sandler reiterated an “overweight” rating on shares of Masimo in a report on Friday, October 18th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Friday, September 20th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $145.33.

Masimo Stock Up 1.3 %

Masimo stock traded up $1.84 during trading on Wednesday, reaching $142.89. 617,861 shares of the company’s stock were exchanged, compared to its average volume of 673,961. Masimo has a 52-week low of $75.36 and a 52-week high of $153.93. The firm has a market cap of $7.60 billion, a price-to-earnings ratio of 95.95 and a beta of 0.99. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09. The company’s 50-day moving average is $128.12 and its two-hundred day moving average is $125.01.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.09. The company had revenue of $496.30 million during the quarter, compared to the consensus estimate of $493.92 million. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The company’s revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.62 earnings per share. On average, analysts predict that Masimo will post 3.88 earnings per share for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.